Multiple clinical data readouts expected in 2026 present opportunity for substantial value creationKOASTAL-2 and -3 on track for consolidated ...
Takeda regains a majority of XOMA Royalty’s royalty interest in mezagitamab (TAK-079) –– XOMA Royalty will be entitled to ...
The latest update is out from Hansoh Pharmaceutical Group Company Limited ( ($HK:3692) ). Hansoh Pharmaceutical Group has signed a license ...
Detailed price information for Gain Therapeutics Inc (GANX-Q) from The Globe and Mail including charting and trades.
Detailed price information for Gain Therapeutics Inc (GANX-Q) from The Globe and Mail including charting and trades.
NEW YORK, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced ...
WATERTOWN, Mass., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company redefining neuroscience drug development, today announced the ...
Neuphoria’s social anxiety disorder program will be discontinued based on the results from the AFFIRM-1 trial. Topline results were announced from a phase 3 trial evaluating BNC210 in patients with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback